Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Addex Rises on Positive Rodent Experiment Results: Zurich Mover

May 21 (Bloomberg) -- Addex Therapeutics Ltd., a Swiss biotechnology company, rose to the highest level in two weeks after saying an experimental molecule influenced growth-hormone concentrations in rodents.

Addex advanced as much as 3.8 percent to 6.80 Swiss francs in Zurich, the highest price since May 7, and was up 3.1 percent at 12:14 p.m. local time, giving the Geneva-based company a market value of 60.5 million Swiss francs ($62.4 million).

Results show that the ADX71441 molecule, depending on its dosage, leads to changes in the concentration of growth hormones, the Geneva-based company said in a statement. The development could provide “an understanding of the therapeutic potential of ADX71441,” Chief Scientific Officer Graham Dixon said in the statement.

Growth-hormone concentrations have been demonstrated to have an effect on anxiety, pain, overactive bladder and alcohol addiction in pre-clinical models, Addex said.

To contact the reporter on this story: Carolyn Bandel in Zurich at cbandel@bloomberg.net

To contact the editor responsible for this story: Frank Connelly at fconnelly@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.